Heart Test Laboratories, Inc. Engages OfferBoard Securities for Capital Raise to Bring Next Gen EKG to Market
OfferBoard
Securities, LLC announces it has been retained by medical device
company Heart Test Laboratories, Inc. to provide investment banking
services and assist with raising capital to bring the next generation
EKG device (MyoVista) to market.
“Heart disease is common and deadly but
treatable if detected early. Unfortunately we still live in a world
where most people find out about their condition through a heart attack
or worse death” said Heart Test Labs Chairman Andrew Simpson. “While
cardiologists have the tools for effective treatment of heart disease,”
continued Simpson, “the big diagnostic gap is identifying at an early
stage who should seek treatment. This is where the MyoVista comes into
play.”
Cardiovascular disease is the leading cause of
deaths worldwide accounting for 17.3 million deaths/yr more then all
cancers combined; and the largest expenditure in healthcare exceeding
$320 billion/yr according to the American Heart Association 2015 Heart
Disease and Stroke Statistics Update. Heart Test Labs developed the
MyoVista to address this epidemic and enable low cost and effective
screening of heart disease at an early stage using propriety technology
and informatics.
“As someone whose family has been personally
affected by heart disease, I am excited for the opportunity to work with
Heart Test Labs in their efforts to bring the MyoVista to market” said
David Lopez, Managing Director for OfferBoard. “Given the vast number of
people affected by this condition, I am confident investors will relate
and appreciate the possibility of the MyoVista becoming the standard of
care in screening for heart disease in the near future.”
Positioned at the forefront of technology
advancement in electrocardiography-based devices, the MyoVista uses
sophisticated algorithms and easy to understand proprietary informatics
to assist a physician to identify heart disease at an early stage. The
MyoVista is expected to be in the hands of physicians and hospitals by
the first quarter of 2016.
To view Heart Test Laboratories' offering page, please visit https://OfferBoard.com/htl
About Heart Test Laboratories, Inc.
Heart Test Laboratories, Inc. develops a
medical device using patented technology that focus on the early
detection of heart disease called MyoVista. By using standard 12-lead
resting ECG protocols, the MyoVista provides an ECG test incorporating
interpretive analysis, plus easy to understand proprietary informatics
that assist a physician in identifying heart disease at an early stage.
The MyoVista provides additional information to physicians in their
decision process to refer patients to a cardiologist for further
diagnostic testing and treatment.
Heart disease kills 7 million people worldwide
each year, more than all cancers combined, and is the largest spend
area in healthcare. The MyoVista helps to address the “diagnostic gap”
in heart disease today, which is the identification of asymptomatic
patients prior to an adverse cardiac event, such as a heart attack. For
more information please visit https://www.hearttestlabs.com.
About OfferBoard Securities
OfferBoard Securities is a national investment
bank and broker dealer with an equity-funding platform, headquartered
in Princeton, New Jersey. OfferBoard Securities advises private
companies raising $2 to $200 million in capital, including mergers,
acquisitions, and divestitures. The OfferBoard team is backed by more
than 75 years of experience from companies including Second Market,
Goldman Sachs, JP Morgan Chase Bank and the Asian Development Bank,
among others. OfferBoard Securities is member FINRA/SIPC. For more information please visit https://www.offerboard.com.
No comments:
Post a Comment